Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
2014 · The Lancet · 4,585 citations
https://doi.org/10.1016/s0140-6736(13)62422-8
H
Holger Eidtmann
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
245
Papers
23.8K
Citations
60
h-index
104
i10-index
Holger Eidtmann is an academic researcher. The author has contributed to research in topics: Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology. The author has an h-index of 60, co-authored 209 publications.
Papers by this author
worksDefinition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 · Journal of Clinical Oncology · 2,602 citations
https://doi.org/10.1200/jco.2011.38.8595
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
2012 · The Lancet · 1,303 citations
https://doi.org/10.1016/s0140-6736(11)61847-3
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
2014 · The Lancet Oncology · 1,014 citations
https://doi.org/10.1016/s1470-2045(14)70160-3
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
2010 · Journal of Clinical Oncology · 550 citations
https://doi.org/10.1200/jco.2009.23.8451
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
2012 · New England Journal of Medicine · 530 citations
https://doi.org/10.1056/nejmoa1111065
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat